These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 3427175)

  • 61. Designing clinical trials with arbitrary specification of survival functions and for the log rank or generalized Wilcoxon test.
    Halpern J; Brown BW
    Control Clin Trials; 1987 Sep; 8(3):177-89. PubMed ID: 3665521
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Planning the size of survival time clinical trials with allowance for stratification.
    Moussa MA
    Stat Med; 1988 May; 7(5):559-69. PubMed ID: 3387715
    [TBL] [Abstract][Full Text] [Related]  

  • 63. How Do the Accrual Pattern and Follow-Up Duration Affect the Hazard Ratio Estimate When the Proportional Hazards Assumption Is Violated?
    Horiguchi M; Hassett MJ; Uno H
    Oncologist; 2019 Jul; 24(7):867-871. PubMed ID: 30201741
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Using permutation tests and bootstrap confidence limits to analyze repeated events data from clinical trials.
    Freedman L; Sylvester R; Byar DP
    Control Clin Trials; 1989 Jun; 10(2):129-41. PubMed ID: 2752763
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Methodological issues in cancer clinical trials: the comparison of therapies.
    Gehan EA
    Biomed Pharmacother; 1988; 42(3):161-5. PubMed ID: 3179400
    [No Abstract]   [Full Text] [Related]  

  • 66. Monitoring clinical trials: conditional or predictive power?
    Spiegelhalter DJ; Freedman LS; Blackburn PR
    Control Clin Trials; 1986 Mar; 7(1):8-17. PubMed ID: 3956212
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Power calculation for the log rank test using historical data.
    Cantor AB
    Control Clin Trials; 1996 Apr; 17(2):111-6. PubMed ID: 8860063
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Power considerations for clinical trials using multivariate time-to-event data.
    Hughes MD
    Stat Med; 1997 Apr; 16(8):865-82. PubMed ID: 9160485
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Sample size requirements and the cost of a randomized clinical trial with repeated measurements.
    Bloch DA
    Stat Med; 1986; 5(6):663-7. PubMed ID: 3823673
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Combining outcome measures: statistical power is irrelevant.
    Senn S
    Biometrics; 1989 Sep; 45(3):1027-8. PubMed ID: 2790115
    [No Abstract]   [Full Text] [Related]  

  • 71. Changes in clinical trial length.
    Pregelj L; Verreynne ML; Hine D
    Nat Rev Drug Discov; 2015 May; 14(5):307-8. PubMed ID: 25924577
    [No Abstract]   [Full Text] [Related]  

  • 72. Subgroup analyses.
    Berry DA
    Biometrics; 1990 Dec; 46(4):1227-30. PubMed ID: 2085637
    [No Abstract]   [Full Text] [Related]  

  • 73. Planning a clinical trial with allowance for cost and patient recruitment rate.
    Moussa MA
    Comput Programs Biomed; 1984; 18(3):173-9. PubMed ID: 6548679
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Case control studies].
    Olsen J
    Nord Med; 1988; 103(6-7):205-7. PubMed ID: 3380678
    [No Abstract]   [Full Text] [Related]  

  • 75. Approaches to sample size estimation in the design of clinical trials--a review.
    Makuch R
    Stat Med; 1985; 4(2):247. PubMed ID: 4023483
    [No Abstract]   [Full Text] [Related]  

  • 76. Trial and measure.
    Scott J
    Nurs Mirror; 1979 Aug; 149(8):33. PubMed ID: 382134
    [No Abstract]   [Full Text] [Related]  

  • 77. Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observation.
    Rubinstein LV; Gail MH; Santner TJ
    J Chronic Dis; 1981; 34(9-10):469-79. PubMed ID: 7276137
    [No Abstract]   [Full Text] [Related]  

  • 78. A Multi-state Model for Designing Clinical Trials for Testing Overall Survival Allowing for Crossover after Progression.
    Xia F; George SL; Wang X
    Stat Biopharm Res; 2016; 8(1):12-21. PubMed ID: 27239255
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Tables of the number of patients required in clinical trials using the logrank test.
    Stein RA
    Stat Med; 1986; 5(1):97-8. PubMed ID: 3961318
    [No Abstract]   [Full Text] [Related]  

  • 80. Determining the required accrual rate for fixed-duration clinical trials.
    Palta M
    J Chronic Dis; 1982; 35(1):73-7. PubMed ID: 7068805
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.